Owkin Bolsters Senior Team With Experienced Pharma Executives to Expand Platform and Strategic Partnerships

Asif Jan and Sezai Taskin join Owkin

Owkin, a startup pioneering Federated Learning and AI technologies for medical research and clinical development, announces two senior hires to boost its platform and expand its strategic life science partnerships.

Today, Asif Jan and Sezai Taskin bring to the Owkin team an accumulated 30 years of experience in the pharmaceutical industry.

Asif Jan joins Owkin as an SVP, Head of Platform & Solutions to lead the development of the Owkin Platform and its federated data network, bringing a unique skill set and experience covering computer science, data science, product and strategy. Prior to this move, Asif served as a Global Head of Personalized Healthcare Analytics in the PHC group for Roche. Asif began a decade-long association with Roche in 2011, covering Informatics, Diagnostics and Pharma. In his early work there, he oversaw the data and solution architecture for clinical data capture, management and analysis solutions supporting clinical studies conducted by the Diagnostics division. In 2014, he moved to the Diagnostics Chief Technology Office leading technology assessment for external data and analytics opportunities in the RWD, digital and bioinformatics domain. He and his team successfully introduced RWD capabilities across global lifecycle, medical and market access teams and opened new possibilities for data-driven evidence generation.

As an SVP of Strategic Business Development, Sezai Taskin will bring his 20 years of experience to develop strategic value-based partnerships with pharma and biotech companies. Sezai joins from AstraZeneca where he was Head of ENHERTU and Daiichi Sankyo Alliance for Europe. Prior to his position at AstraZeneca, Sezai was a recognized business leader in hematology and oncology at Abbvie and Roche, at the regional and international level. He supervised the launch, marketing and commercialization of numerous leading franchises across multiple therapeutic areas. Throughout his experience, he has always pushed for innovative approaches to deliver the right drug for the right patient, leveraging advanced technologies and data-driven solutions to improve patient outcomes.

Thomas Clozel, Owkin Co-founder and Chief Executive Officer said: "We are thrilled to have Asif and Sezai join our team. Both bring a wealth of experience across healthcare, pharma and technology. We believe they will boost our efforts to scale our federated network of academic hospital partners and our solutions across pharma clients." 

About Owkin:

Owkin is a French-American startup that specializes in AI and Federated Learning for medical research. It was co-founded in 2016 by Dr Thomas Clozel M.D., a clinical research doctor and former assistant professor in clinical hematology, and Dr Gilles Wainrib, Ph.D., a pioneer in the field of artificial intelligence in biology. Owkin has recently published groundbreaking research at the frontier of AI and medicine in Nature Medicine, Nature Communications and Hepatology.

Press Contacts:

Talia Lliteras - Tél. +33 7 87 21 81 90 - talia.lliteras@owkin.com

Source: Owkin

About Owkin

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

14/16 Bd Poissonnière

More Press Releases